Head-To-Head Review: Antibe Therapeutics (OTCMKTS:ATBPF) and Anthem (NASDAQ:ANTX)

Antibe Therapeutics (OTCMKTS:ATBPF) and Anthem (NASDAQ:ANTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability and analyst recommendations.

Earnings and Valuation

This table compares Antibe Therapeutics and Anthem”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Antibe Therapeutics	N/A	N/A	-$14.73 million	($0.25)	-0.86
Anthem	N/A	N/A	-$35.17 million	($1.10)	-4.32

Anthem is trading at a lower price-to-earnings ratio than Antibe Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

90.5% of Anthem shares are owned by institutional investors. 9.0% of Antibe Therapeutics shares are owned by company insiders. Comparatively, 24.5% of Anthem shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and price targets for Antibe Therapeutics and Anthem, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Antibe Therapeutics	0	0	0	0	0.00
Anthem	1	0	1	0	2.00

Anthem has a consensus price target of $9.00, suggesting a potential upside of 89.47%. Given Anthem’s stronger consensus rating and higher probable upside, analysts plainly believe Anthem is more favorable than Antibe Therapeutics.

Profitability

This table compares Antibe Therapeutics and Anthem’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Antibe Therapeutics	N/A	-56.48%	-29.07%
Anthem	N/A	-52.35%	-47.25%

Volatility and Risk

Antibe Therapeutics has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, Anthem has a beta of -0.95, indicating that its stock price is 195% less volatile than the S&P 500.

Summary

Anthem beats Antibe Therapeutics on 6 of the 11 factors compared between the two stocks.

About Antibe Therapeutics

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

About Anthem

Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States. It operates through three segments: Commercial & Specialty Business, Government Business, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small group, individual, Medicaid, and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; traditional indemnity plans and other hybrid plans, such as consumer-driven health plans; and hospital only and limited benefit products. The company also provides a range of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs, and other administrative services. In addition, it offers an array of specialty and other insurance products and services, such as dental, vision, life and disability insurance benefits, radiology benefit management, and analytics-driven personal health care guidance; and Medicare administrative services. Further, the company provides services to the federal government in connection with the Federal Employee Program; and operates as a licensee of the Blue Cross and Blue Shield Association. As of December 31, 2017, it served 40.2 million medical members through its affiliated health plans. The company was formerly known as WellPoint, Inc. and changed its name to Anthem, Inc. in December 2014. Anthem, Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.